Ranbaxy reportedly near $100M generics deal

India's Ranbaxy Laboratories is reportedly close to buying the Russian generic drug company Akrikhin for about $100 million. The Business Standard reported that Ranbaxy was looking to expand its presence in the Russian market. If it completes the deal it will mark the latest in a string of acquisitions in Italy, Spain, Romania and Belgium. Ranbaxy has been scouting the Canadian market as well.

- check out this report on Ranbaxy